<?xml version="1.0" encoding="UTF-8"?>
<p>Recently, mirabegron, a Î²3-adrenoceptor agonist, was approved in North America, Europe, Japan and Australia for the treatment of an overactive bladder.
 <sup>
  <xref rid="b9-1040710" ref-type="bibr">9</xref>
 </sup> Here, we report the results of a phase II study that tested the efficacy of mirabegron in patients with 
 <italic>JAK2</italic>-V617F-positive MPN.
</p>
